Scarica l'app Stockscreener
83.45
0.82%
-0.69
Precedente Chiudi:
$84.14
Aprire:
$84.54
Volume 24 ore:
927.84K
Relative Volume:
1.72
Capitalizzazione di mercato:
$8.85B
Reddito:
$612.78M
Utile/perdita netta:
$-86.37M
Rapporto P/E:
-51.83
EPS:
-1.61
Flusso di cassa netto:
$-62.91M
1 W Prestazione:
+0.51%
1M Prestazione:
-2.56%
6M Prestazione:
+10.46%
1 anno Prestazione:
+27.83%
Intervallo 1D:
$82.76
$85.03
Intervallo di 1 settimana:
$82.19
$89.12
Portata 52W:
$62.78
$93.45
Intra Cellular Therapies Inc Stock (ITCI) Company Profile
Nome
Intra Cellular Therapies Inc
Settore
Telefono
(646) 440-9333
Indirizzo
135 ROUTE 202/206, BEDMINSTER, NY
Confronta ITCI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ITCI
Intra Cellular Therapies Inc
|
83.45 | 8.85B | 612.78M | -86.37M | -62.91M | -0.87 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Intra Cellular Therapies Inc Stock (ITCI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-06 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-12-11 | Iniziato | TD Cowen | Outperform |
| 2023-04-20 | Iniziato | Morgan Stanley | Overweight |
| 2022-08-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-22 | Iniziato | Piper Sandler | Neutral |
| 2022-02-16 | Iniziato | Goldman | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2020-12-15 | Iniziato | BofA Securities | Buy |
| 2020-12-10 | Iniziato | Goldman | Buy |
| 2020-02-20 | Iniziato | Evercore ISI | Outperform |
| 2020-01-31 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-24 | Reiterato | Canaccord Genuity | Buy |
| 2019-08-12 | Iniziato | Jefferies | Buy |
| 2018-02-26 | Iniziato | JP Morgan | Overweight |
| 2018-02-08 | Iniziato | RBC Capital Mkts | Outperform |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-11-08 | Aggiornamento | SunTrust | Hold → Buy |
| 2017-09-07 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-08-30 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2017-08-24 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-08-23 | Aggiornamento | Leerink Partners | Mkt Perform → Outperform |
| 2017-05-02 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2017-05-02 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2017-05-01 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-12-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-09-29 | Reiterato | RBC Capital Mkts | Outperform |
| 2016-09-29 | Downgrade | SunTrust | Buy → Neutral |
Mostra tutto
Intra Cellular Therapies Inc Borsa (ITCI) Ultime notizie
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid patent challenges - Investing.com India
Intra-Cellular Therapies' SWOT analysis: CAPLYTA drives stock potential amid patent challenges By Investing.com - Investing.com South Africa
Geode Capital Management LLC Increases Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
S&P 500 Futures Drop in Premarket Trading; Intra-Cellular Therapies, Avantor Lag - Barron's
Franklin Resources Inc. Purchases 155,655 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
(ITCI) Technical Pivots with Risk Controls - Stock Traders Daily
State Street Corp Has $136.02 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Y Intercept Hong Kong Ltd Trims Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies' SWOT analysis: Caplyta's success drives stock potential - Investing.com
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College of Neuropsychopharmacology Annual Meeting - The Manila Times
Intra-Cellular Therapies Presents Data from the CAPLYTA - GlobeNewswire
Intra-Cellular Therapies Presents Data from the CAPLYTA Adjunctive MDD Phase 3 Program at the American College - EIN News
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Holdings Decreased by Wellington Management Group LLP - MarketBeat
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move - Seeking Alpha
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Point72 Asset Management L.P. - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by BNP Paribas Financial Markets - MarketBeat
Insider Selling: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) CEO Sells 51,000 Shares of Stock - MarketBeat
Intra-cellular Therapies CEO sells $8.72 million in stock By Investing.com - Investing.com UK
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 11,104 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD - MSN
Study Estimates 5 Million People Could Benefit from Magic Mushrooms for Depression Treatment - Managed Healthcare Executive
(ITCI) Investment Analysis and Advice - Stock Traders Daily
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Parkman Healthcare Partners LLC - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Bank of Montreal Can - MarketBeat
Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Expected To Breakeven In The Medium-Term - Simply Wall St
HighVista Strategies LLC Has $548,000 Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Erste Asset Management GmbH Purchases Shares of 23,400 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Seeks FDA Approval for Caplyta as Additional Treatment for Depression - Managed Healthcare Executive
Intra-Cellular Eyes Depression Approval for Caplyta as Stock Flies Under the Radar - BioSpace
Intra-Cellular Ther (ITCI-Q) QuotePress Release - The Globe and Mail
Point72 Hong Kong Ltd Sells 38,075 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for CAPLYTA® (lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy - The Manila Times
Intra-Cellular Therapies Submits Supplemental New Drug - GlobeNewswire
Intra-Cellular Therapies Says FDA Approved Caplyta to Treat Bipolar Depression, Shares up - Marketscreener.com
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Bellevue Group AG - MarketBeat
Point72 Europe London LLP Lowers Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
54,629 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Purchased by Edgestream Partners L.P. - MarketBeat
Cerity Partners LLC Has $3.23 Million Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies stock rated Outperform by Mizuho, with 13% stock rise post-earnings - Investing.com UK
Why Is Intra-Cellular (ITCI) Up 2.2% Since Last Earnings Report? - Yahoo Finance
Vestal Point Capital LP Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Suvretta Capital Management LLC Has $105.29 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Stake Decreased by Charles Schwab Investment Management Inc. - MarketBeat
Fmr LLC Sells 116,146 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
How Intra-Cellular surprised Wall Street by breaking character - BioPharma Dive
Cynosure Group LLC Purchases 8,909 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Algert Global LLC Reduces Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Natixis Advisors LLC Has $1.80 Million Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) - MarketBeat
Analysts Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $97.23 - MarketBeat
Intra Cellular Therapies Inc Azioni (ITCI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Intra Cellular Therapies Inc Azioni (ITCI) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Option Exercise |
12.73 |
51,000 |
649,230 |
1,121,329 |
| Mates Sharon | Chairman and CEO |
Dec 04 '24 |
Sale |
85.80 |
51,000 |
4,375,659 |
1,070,329 |
| Mates Sharon | Chairman and CEO |
Dec 05 '24 |
Sale |
84.08 |
51,697 |
4,346,842 |
1,070,329 |
2.89%
1.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):